Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.

@article{Trembley2012NanoencapsulatedAS,
  title={Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.},
  author={Janeen H. Trembley and Gretchen M. Unger and Vicci L. Korman and Diane K. Tobolt and Zygmunt Kazimierczuk and Lorenzo A Pinna and Betsy T. Kren and Khalil Ahmed},
  journal={Cancer letters},
  year={2012},
  volume={315 1},
  pages={48-58}
}
CK2, a pleiotropic Ser/Thr kinase, is an important target for cancer therapy. We tested our novel tenfibgen-based nanocapsule for delivery of the inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) and an siRNA directed against both CK2α and α' catalytic subunits to prostate cancer cells. We present data on the TBG nanocapsule itself and on CK2 inhibition or downregulation in treated cells, including effects on Nuclear Factor-kappa B (NF-κB) p65. By direct comparison of two CK2… CONTINUE READING

From This Paper

Topics from this paper.
11 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…